JP Morgan 2025: GSK acquires IDRx in $1.15bn deal

GSK is acquiring US biotech company IDRx for $1.15bn, enhancing its oncology portfolio with IDRX-42, a promising TKI for treating gastrointestinal cancers. This deal reflects GSK's strategic focus on addressing unmet medical needs in oncology.